The Food and Drug Administration has not evaluated these statements. This product is not designed to diagnose, treat, cure, or prevent any medical condition. Not intended for human consumption.
Cagrisema is a research peptide formulation combining cagrilintide and semaglutide analogs. Experimental studies commonly investigate its interaction with incretin-related signaling pathways and metabolic regulatory systems.